What's in SecuraBio's pipeline?

SecuraBio has 3 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with SecuraBio's portfolio?

No competitive overlap detected.

Subscribe to /feed/company/securabio.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

SecuraBio pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Drug	Generic	Phase	Class	Target	Area	First approval
IPI-145	IPI-145	phase 3	PI3K delta/gamma inhibitor	PI3K delta (PI3Kδ), PI3K gamma (PI3Kγ)	Oncology

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for SecuraBio:

Drug Landscape (2026). SecuraBio — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/securabio. Accessed 2026-05-13.